Compare Quest Diagnostics Inc (DGX) vs Marvell Technology Inc (MRVL) Price & Performance

Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.

The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.

Marvell Technology (MRVL) trades at $275.28, down 3.3% in the last session, but maintains strong technical momentum with bullish moving averages and support at $267. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $1.1. Revenue growth accelerated to 42% in fiscal 2026, driven by data center products comprising 74% of sales. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $327.86 price target, representing 19% upside potential.

Marvell's AI-driven growth story appears compelling with custom chip deals with hyperscalers potentially generating $120 billion in cumulative revenue. However, high valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) present risks. The stock's 210% YTD gain suggests much optimism is priced in, requiring continued execution on the $18 billion fiscal 2028 revenue guidance to justify current levels.